Actively Recruiting
Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS
Led by The Second Affiliated Hospital of Chongqing Medical University · Updated on 2025-06-04
500
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
Sponsors
T
The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor
U
University-Town Hospital of Chongqing Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
1. A predictive model for NARDS was established based on perinatal risk factors. Multivariate Logistic regression analysis was used to screen the independent prenatal risk factors for NARDS. A Logistic regression model was constructed using the above independent risk factors and quantified in a nomogram to construct a visualization model for prenatal prediction of NARDS. 2. The role of ACS in the prevention and treatment of ARDS in near-term/full-term infants. For neonates with a probability greater than 80% in the prediction model of ARDS, at least one ACS was given before the termination of pregnancy. The GC level of cord blood (taken at birth) and the mRNA levels of α-ENaC, Na-K-atpase and SGK1 in nasal epithelium were measured within 2 hours and 1 day after birth in the ACS intervention group and the control group. The occurrence and severity of pulmonary edema, the occurrence and severity of ARDS, and the mortality rate of NARDS were evaluated by lung ultrasound. The indexes of the two groups were compared horizontally and longitudinally.
CONDITIONS
Official Title
Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnant women with a predicted risk greater than 80% for neonatal acute respiratory distress syndrome based on the prenatal prediction model
- Pregnant women who agree to receive antenatal corticosteroid intervention
- Patients who have given consent to participate in the study
You will not qualify if you...
- Pregnant women with a predicted risk less than 80% for neonatal acute respiratory distress syndrome
- Patients who refuse to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
Actively Recruiting
Research Team
L
Li Wang, MD,PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here